These interconnected effects raise concerns for clinicians, underscoring the need to monitor receptor tolerance, metabolic health, and cardiovascular risk throughout therapy
In a 72-week study, people living with obesity but without type 2 diabetes taking tirzepatide lost more weight than people taking semaglutide
Earlier amylin analogs like pramlintide were short-acting and needed dosing with every meal, which made them a hassle and limited their reach
It increases the levels of incretins hormones which are naturally produced by the stomach when you eat, causing you to feel fuller quicker and satiate your hunger - taking away a big pain point for when you're trying to lose weight
In addition, more than 40% of CagriSema-treated participants achieved weight loss of at least 25%, versus 6% of patients taking cagrilintide, 16.2% of those on semaglutide and 0.9% of participants in the placebo group